Altimmune Inc (NASDAQ: ALT)’s stock price has dropped by -4.41 in relation to previous closing price of 6.58. Nevertheless, the company has seen a loss of -2.18% in its stock price over the last five trading days. accesswire.com reported 2024-07-25 that LAS VEGAS, NV / ACCESSWIRE / July 25, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, released its transaction volume for Q1 and Q2 2024 combined. According to the company, ALT5’s transaction volume reached US$879 million for the first two quarters of 2024, ending June 30, 2024, which represents a year-over-year increase of 99%.
Is It Worth Investing in Altimmune Inc (NASDAQ: ALT) Right Now?
The 36-month beta value for ALT is also noteworthy at 0.12. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ALT is 70.34M, and at present, short sellers hold a 32.14% of that float. The average trading volume of ALT on July 30, 2024 was 3.53M shares.
ALT’s Market Performance
ALT’s stock has seen a -2.18% decrease for the week, with a -5.41% drop in the past month and a -1.64% fall in the past quarter. The volatility ratio for the week is 6.41%, and the volatility levels for the past 30 days are at 7.69% for Altimmune Inc The simple moving average for the last 20 days is -9.77% for ALT’s stock, with a simple moving average of -14.41% for the last 200 days.
Analysts’ Opinion of ALT
Goldman, on the other hand, stated in their research note that they expect to see ALT reach a price target of $13. The rating they have provided for ALT stocks is “Neutral” according to the report published on January 24th, 2024.
Goldman gave a rating of “Neutral” to ALT, setting the target price at $6 in the report published on March 22nd of the previous year.
ALT Trading at -9.69% from the 50-Day Moving Average
After a stumble in the market that brought ALT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.61% of loss for the given period.
Volatility was left at 7.69%, however, over the last 30 days, the volatility rate increased by 6.41%, as shares sank -12.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.93% lower at present.
During the last 5 trading sessions, ALT fell by -1.63%, which changed the moving average for the period of 200-days by +121.15% in comparison to the 20-day moving average, which settled at $6.93. In addition, Altimmune Inc saw -44.09% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALT starting from Drutz David, who purchase 300 shares at the price of $2.88 back on Aug 15 ’23. After this action, Drutz David now owns 29,785 shares of Altimmune Inc, valued at $862 using the latest closing price.
Stock Fundamentals for ALT
Current profitability levels for the company are sitting at:
- -215.96 for the present operating margin
- -81.04 for the gross margin
The net margin for Altimmune Inc stands at -226.26. The total capital return value is set at -0.5. Equity return is now at value -54.46, with -49.42 for asset returns.
Based on Altimmune Inc (ALT), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -131.81. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 3689.38.
Currently, EBITDA for the company is -83.03 million with net debt to EBITDA at 0.93. When we switch over and look at the enterprise to sales, we see a ratio of 884.26. The receivables turnover for the company is 0.16for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.55.
Conclusion
In summary, Altimmune Inc (ALT) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
